Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX Hold and COVID-19 Booster in RA
NCT05313061Phase 3Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in rheumatoid arthritis (RA), sponsored by Seoul National University Hospital. Primary endpoint: COVID-19 antibody titer at 2 weeks. Status: unknown.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05313061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313061.